Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are considered the first line treatment for a subset of EGFR-mutated non-small cell lung cancer (NSCLC) patients. Although transformation to small cell lung cancer (SCLC) is one of the known mechanisms of resistance to EGFR TKIs, it is not certain whether transformation to SCLC is exclusively found as a mechanism of TKI resistance in EGFR-mutant tumors. Methods: We identified six patients with primary lung adenocarcinoma that showed transformation to SCLC on second biopsy (n = 401) during a 6-year period. Clinicopathologic information was analyzed and EGFR mutation results were compared between initial and second biopsy samples. Results: Six patients showed transformation from adenocarcinoma to SCLC, of which four were pure SCLCs and two were combined adenocarcinoma and SCLCs. Clinically, four cases were EGFR-mutant tumors from non-smoking females who underwent TKI treatment, and the EGFR mutation was retained in the transformed SCLC tumors. The remaining two adenocarcinomas were EGFR wild-type, and one of these patients received EGFR TKI treatment. Conclusions: NSCLC can acquire a neuroendocrine phenotype with or without EGFR TKI treatment.
Abstract
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are considered the first line treatment for a subset of EGFR-mutated non-small cell lung cancer (NSCLC) patients. Although transformation to small cell lung cancer (SCLC) is one of the known mechanisms of resistance to EGFR TKIs, it is not certain whether transformation to SCLC is exclusively found as a mechanism of TKI resistance in EGFR-mutant tumors. Methods: We identified six patients with primary lung adenocarcinoma that showed transformation to SCLC on second biopsy (n = 401) during a 6-year period. Clinicopathologic information was analyzed and EGFR mutation results were compared between initial and second biopsy samples. Results: Six patients showed transformation from adenocarcinoma to SCLC, of which four were pure SCLCs and two were combined adenocarcinoma and SCLCs. Clinically, four cases were EGFR-mutant tumors from non-smoking females who underwent TKI treatment, and the EGFR mutation was retained in the transformed SCLC tumors. The remaining two adenocarcinomas were EGFR wild-type, and one of these patients received EGFR TKI treatment. Conclusions: NSCLC can acquire a neuroendocrine phenotype with or without EGFR TKI treatment.
참고문헌 (20)
- Goldstraw P, "Non-small-cell lung cancer", Lancet, 378, pp.1727~1740 (2011)
- Oser MG, "Transformation from non-small-cell lung cancer to small-cell lung cancer: molecu lar drivers and cells of origin", Lancet Oncol, 16, pp.e165~e172 (2015)
- Moiseenko VM, "Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)", Vopr Onkol, 56, pp.20~23 (2010)
- Engelman JA, "Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer", Clin Cancer Res, 14, pp.2895~2899 (2008)
- Yu HA, "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers", Clin Cancer Res, 19, pp.2240~2247 (2013)
- Sequist LV, "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors", Sci Transl Med, 3, pp.75ra~26 (2011)
- Zakowski MF, "EGFR mutations in small-cell lung cancers in patients who have never smoked", N Engl J Med, 355, pp.213~215 (2006)
- van Riel S, "A patient with simultaneously appearing adenocarcinoma and smallcell lung carcinoma harbouring an identical EGFR exon 19 mutation", Ann Oncol, 23, pp.3188~3189 (2012)
- Morinaga R, "Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation", Lung Cancer, 58, pp.411~413 (2007)
- Norkowski E, "Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology", J Thorac Oncol, 8, pp.1265~1271 (2013)
- Watanabe S, "Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma", Lung Cancer, 82, pp.370~372 (2013)
- Kim WJ, "Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor", Thorac Cance, 6, pp.800~804 (2015)
- 이보람, "KRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing", Journal of Pathology and Translational Medicine, 48(2), pp.100~107 (2014), 대한병리학회[DOI]
- 안수민, "Comparison of Three BRAF Mutation Tests in Formalin-Fixed Paraffin Embedded Clinical Samples", Journal of Pathology and Translational Medicine, 47(4), pp.348~354 (2013), 대한병리학회[DOI]
- Pao W, "Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer:current knowledge and future directions", J Clin Oncol, 23, pp.2556~2568 (2005)
- Miyamoto S, "Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib", Jpn J Clin Oncol, 46, pp.170~173 (2016)
- Kogo M, "Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor", Lung Cancer, 90, pp.364~368 (2015)
- Caumont C, "Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma", Lung Cancer, 92, pp.15~18 (2016)
- Sutherland KD, "Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lun", Cancer Cell, 19, pp.754~764 (2011)
- Ham JS, "Two cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD9291treatment", J Thorac Oncol, 11, pp.E1~E4 (2016)